Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Based upon animal experiments and early clinical trials, neurokinin-1 receptor antagonists showed promise as novel antidepressants. Subsequently, however, more extensive clinical trials did not reveal evidence of efficacy in depression. The development of novel antidepressants will require a better understanding of the neural basis of antidepressant action in humans.

Original publication

DOI

10.1192/bjp.bp.107.037879

Type

Journal article

Journal

Br J Psychiatry

Publication Date

10/2007

Volume

191

Pages

282 - 284

Keywords

Animals, Antidepressive Agents, Clinical Trials as Topic, Depressive Disorder, Drug Design, Humans, Models, Animal, Morpholines, Neurokinin-1 Receptor Antagonists, Substance P